ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
integrated specialty pharmaceutical firm that develops and markets branded and generic medicines The analyst notes that ANI's business model has significantly transformed, shifting from a primary emphasis on generics to a new focus on integrating high-margin brand assets aimed at rare diseases. Cortrophin Gel (adrenocorticotropic hormone (ACTH)), the company's lead asset, has been the centerpiece of that evolution. Cortrophin gel sales more than doubled to $49.2 million in the second quarter of 2024, driven primarily by increased volume. The company raised the fiscal year 2024 Cortrophin gel outlook from $170 million-$180 million to $185 million-$195 million The FDA approved Cortrophin Gel in 2021, which covers several autoimmune diseases. At that time, there was only one other ACTH player, Mallinckrodt Plc's (OTC: MNKTQ ) Acthar Gel. The company and the drug have been associated with payer challenges, negative attention associated with the Medicaid rebate-related litigation and
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- 1 Growth Stock to Target This Week and 2 to Avoid [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $85.00 price target on the stock.MarketBeat
- ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why [Yahoo! Finance]Yahoo! Finance
- ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its price target raised by analysts at Guggenheim from $84.00 to $86.00. They now have a "buy" rating on the stock.MarketBeat
ANIP
Earnings
- 2/28/25 - Beat
ANIP
Sec Filings
- 3/11/25 - Form 8-K
- 3/10/25 - Form 4
- 3/7/25 - Form 4
- ANIP's page on the SEC website